Aller au contenu principal
2025 conference-abstract

PS19.3: Developing strategies for human microglia-to-neuron conversion.

0Citations signalées, ce qui n’est pas une note de qualité
2Institutions déclarées
1Pays d’affiliation déclarés

Rattachement africain : jp. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

Introduction: Direct reprogramming of somatic cells into other lineages without going through an intermediate pluripotent state is a promising approach for manipulating cell fate, offering both speed and efficiency in generating specific cell types. We have previously shown that a single transcription factor, NeuroD1, can directly convert mouse microglia into neurons within a week. Furthermore, in vivo reprogramming of microglia in a stroke model mouse significantly improved neurological function. However, neuronal conversion of human microglia, which is critically important for clinical applications, has not yet been achieved. In this study, we attempt to address this gap. Methods & Results: Firstly, microglia were differentiated from human induced pluripotent stem cells (hiPSCs) and confirmed to have microglial characteristics based on gene expression patterns. While hiPSCs could differentiate into neurons with nearly 100% efficiency upon NeuroD1 expression, hiPSC-derived microglia (hiPSMG) were hardly converted into neurons despite high expression of NeuroD1. Therefore, we hypothesized that, unlike mouse microglia, a reprogramming barrier that inhibits the pioneer function of NeuroD1 is constructed during the differentiation of hiPSCs into human microglia. To explore the human-specific reprogramming barrier, we performed genome-wide CRISPR-Cas9 knockout screening in hiPSMG. As a result, random gene knockout allowed NeuroD1 expression to induce a small but detectable number of neurons from hiPSMG. We are currently investigating sgRNA enrichment in converted neurons to identify candidate barrier genes. We also plan to knock out these candidate genes in hiPSMG and assess neuronal conversion efficiency via NeuroD1 expression. Additionally, we have established in vivo-like experimental platforms focused on human microglia, including brain organoids co-cultured with hiPSMG, and immunodeficient mice transplanted with hiPSMG. We will perform direct neuronal conversion in these in vivo conditions. Conclusion: We have revealed that human microglia establish a reprogramming barrier against NeuroD1. We are actively working to identify and overcome this reprogramming barrier to enable successful neuronal conversion of human microglia. If successful, our study will provide critical insights into human microglial reprogramming and bring us one step closer to developing novel therapeutic strategies for neurological disorders.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
PS19.3: Developing strategies for human microglia-to-neuron conversion.
Date Crossref
01/10/2025
Éditeur
Ovid Technologies (Wolters Kluwer Health)
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Les institutions déclarées

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

Computational Drug Discovery MethodsRNA Interference and Gene DeliveryNuclear Receptors and Signaling

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.